Dr. Abel A. Pavía, Mexico

Abel-Pavia

Dr. Abel A. Pavía

Clinical and Interventional Cardiology

Mexico

Dr. Abel A. Pavía currently works with the Clinical and Interventional Cardiology Department of Centro Médico ABC. Previously, he held member positions with the Mexican Registry of Interventional Procedures Committee (2013-2015) the Academic Board Sociedad Mexicana de Cardiología Intervencionista (2015-2017). Additionally, he was the President of the Atherosclerosis Committee (Sociedad Mexicana de Cardiología) (2015-2017), a fellow of the American College of Cariology (2016), and the Deputy Secretary-General for the Sociedad de Cardiología Intervencionista de México (2018-2019). Furthermore, he was the local investigator of the SIGNIFY and PARADIGM studies. He also was the National Coordinator of the Internacional Multicenter trial study S6593-006 Efficacy and safety of fixed-dose combination Perindopril 5 mg/ Indapamide 1.25 mg/ Amlodipine 5 mg versus Perindopril 5 mg/Indapamide 1.25 mg single pill
in patients with uncontrolled essential hypertension
after one month of treatment by perindopril 5 mg/ Indapamide 1.25  single pill with conditional titration based on blood pressure control up to perindopril 10 mg/indapamide 2.5 mg / amlodipine 10 mg.

Dr. Pavía has published many books and papers including:

  • Safety and efficacy of enoxaparin vs unfractionated Heparin in patients with Non-ST-segment elevation acute coronary syndrome who received tirofiban and aspirin. Phase A. TIMI 21 trial.
  • Early intensive vs delay conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial. TIMI 21 trial
  • Capitulo epidemiología de las enfermedades cardiovasculares
  • Epidemilogía de las enfermedades cardiovasculares
  • Primer consenso mexicano sobre el diagnóstico y tratamiento de las dislipidemias
  • Effectiveness and Safety of Ezetamibe Added to Statin Therapy in Patients with Primary Dyslipidemia not Achieving the LDL-C Treatment Goal on Statin Monotherapy.
  • Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial
  • Changes in calculated coronary heart disease risk using proactive multifactorial intervention versus continued usual care in Latin-American and non-Latin-American patients enrolled in the CRUCIAL trial
  • Consenso de la Sociedad Mexicana de Cardiología en el diagnóstico y tratamiento de las dislipidemias y aterosclerosis (en prensa)
  • Consenso Mexicano para el diagnóstico y tratamiento de las dislipidemias y aterosclerosis (en revisión)